Degarelix is unlikely to be cost-effective compared to triptorelin plus short-term antiandrogen in the management of advanced prostate cancer with respect to the usual thresholds of cost-effectiveness used in the UK: £20,000-30,000 per QALY gained (used by the National Institute for Health and Clinical Excellence).
Arquitetura e UrbanismoArquitetura e UrbanismoArquitetura e UrbanismoArquitetura e Urbanismo
Arquitetura e UrbanismoArquitetura e UrbanismoArquitetura e UrbanismoArquitetura e Urbanismo